BOGLARKA TUROS: Open Payments
NPI 1679244735 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$836 in 28 payments from 12 companies in 2025. Trend: 2023 $568 · 2024 $1,190 · 2025 $836
Food & beverage: $836
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 5 | $161 |
| Edwards Lifesciences Corporation | 3 | $159 |
| Actelion Pharmaceuticals US, Inc. | 3 | $106 |
| BridgeBio Pharma, Inc. | 3 | $84 |
| ABIOMED | 1 | $52 |
| Merck Sharp & Dohme LLC | 2 | $51 |
| Teleflex LLC | 2 | $50 |
| AstraZeneca Pharmaceuticals LP | 2 | $47 |
| Amgen Inc. | 3 | $45 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $37 |
Products named: LEQVIO, Attruby, OPSUMIT, VERQUVO, WAINUA, REPATHA, JARDIANCE, OPSYNVI.
Industry payments across TX — which companies pay providers there.
